However, contradictory findings of changes in CB1R expression [387,388,389,390,391,392], and a lack of correlation between the CB1R and AD molecular markers or cognition [393], highlight a need to research non-CB1R components of the endocannabinoid system for AD. This evidence concerns the gene CNR1 and Alzheimer disease.